Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Oncotarget Year : 2016

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Abstract

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

Domains

Cancer
Fichier principal
Vignette du fichier
PDFEqu14.pdf (6.63 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-01319327 , version 1 (20-05-2016)

Identifiers

  • HAL Id : inserm-01319327 , version 1
  • PUBMED : 27172791

Cite

Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, et al.. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget, 2016. ⟨inserm-01319327⟩
246 View
154 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More